EXTRACORPOREAL IMMUNOADSORPTION FOR THE SPECIFIC REMOVAL OF LIPOPROTEIN (A) (LP(A) APHERESIS) - PRELIMINARY CLINICAL-DATA

被引：36
作者：
POKROVSKY, SN [1 ]
SUSSEKOV, AV [1 ]
AFANASIEVA, OI [1 ]
ADAMOVA, IY [1 ]
LYAKISHEV, AA [1 ]
KUKHARCHUK, VV [1 ]
机构：
[1] CARDIOL RES CTR,INST CLIN CARDIOL,MOSCOW 121552,RUSSIA
来源：
CHEMISTRY AND PHYSICS OF LIPIDS | 1994年 / 67-8卷
关键词：
LIPOPROTEIN (A); APOLIPOPROTEIN (A); ATHEROSCLEROSIS; APHERESIS; IMMUNOSORBENT;
D O I：
10.1016/0009-3084(94)90153-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The extracorporeal procedure for the specific removal of lipoprotein (a) (Lp(a)) from human plasma - Lp(a) apheresis - was applied to the treatment of three patients with coronary artery disease documented by angiography. Their initial lipid levels were as follows: total cholesterol, 210-230 mg/dl; low-density lipoprotein (LDL) cholesterol, 140-160 mg/dl; Lp(a), 90-120 mg/dl. The patients underwent a total of 168 procedures without significant side effects. Lp(a) apheresis reduced the Lp(a)level by removing up to 88% of Lp(a). Other plasma compounds, including LDL and plasminogen, remained practically unchanged. Lp(a) apheresis appears to be a unique, effective and specific method for lowering the Lp(a) level. Additional trials are needed to evaluate the clinical effect of this treatment.
引用
收藏
页码：323 / 330
页数：8
相关论文
共 3 条
  • [1] Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity
    Pokrovsky, S. N.
    Afanasieva, O. I.
    Safarova, M. S.
    Balakhonova, T. V.
    Matchin, Yu. G.
    Adamova, I. Yu.
    Konovalov, G. A.
    Ezhov, M. V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 30 : 166 - 173
  • [2] Heparin-induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: Technique and first clinical results
    Susca, M
    THERAPEUTIC APHERESIS, 2001, 5 (05): : 387 - 393
  • [3] Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease; [Klinischer Nutzen der Langzeit-Lipoproteinapherese bei Patienten mit schwerer Hypercholesterinämie oder Lp(a)-Hyperlipoproteinämie und progredienter kardiovaskulärer Erkrankung]
    Heigl F.
    Hettich R.
    Lotz N.
    Reeg H.
    Pflederer T.
    Osterkorn D.
    Osterkorn K.
    Klingel R.
    Clinical Research in Cardiology Supplements, 2015, 10 (Suppl 1) : 8 - 13
1